Director's Dealings

RNS Number : 2839M

hVIVO plc

04 January 2019

 

hVIVO PLC

("hVIVO" or the "Company")

 

Director's Dealings

London, UK, 4 January 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that application has been made to AIM for the admission of 14,115 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of his letter of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Winschel had entered into a binding commitment to purchase £4,000 of hVIVO plc new ordinary shares per quarter.

The New Ordinary Shares represent Mr Winschel's investment for the quarter ended 31 December 2019.  On 4 January 2019, Mr Winschel invested in an additional 14,115 ordinary shares, at a price of 28.24 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 80,607,707 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 10 January 2019.  Following Admission, Mr Winschel will be interested in a total of 93,673 ordinary shares of 5.0p in the Company, representing 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Jim Winschel
2	Reason for the notification
a)	Position/ status	Non-Executive Director
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Jim Winschel 28.34 14,115
e)	Aggregated information - Aggregated volume - Price - Aggregated total	14,115 28.34 £4,000.19
f)	Date of the transaction	4 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc	[phone]
Trevor Phillips (Executive Chairman)
Fleur Wood (Director, Investor Relations)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting	[phone]
Simon Conway / Victoria Foster Mitchell

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.

 

END

 

 

DSHUGURAGUPBGAC